Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2

Author: American Society of Clinical Oncology (ASCO) May 26, 2026 Duration: 19:00

Dr. Joshua Reuss returns to the podcast to discuss the update to the living guideline on stage IV NSCLC with driver alterations. The conversation focuses on new cancer treatment strategies for patients with advanced NSCLC and EGFR mutations, including classical EGFR alterations (exon 19 deletions, exon 21 L858R substitution) and rarer alterations (exon 20 insertion mutations). Dr. Reuss discusses results from clinical trials, including MARIPOSA and CHRYSALIS-2 and how these impacted first-line and subsequent line treatment recommendations. He looks to the future on what new evidence and potential updates are in the pipeline for this living guideline.

Read the full living guideline "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, ASCO Living Guideline Version 2026.3.1" 

LINK TO FULL TRANSCRIPT


The ASCO Guidelines podcast, from the American Society of Clinical Oncology, serves as an authoritative audio companion for oncology professionals. Each episode delves into the rationale and practical application of the society's latest evidence-based clinical practice guidance. You'll hear directly from the experts who helped develop these critical recommendations, gaining a deeper understanding of the data and discussions that shape contemporary cancer care. This podcast provides a vital channel for staying current in a rapidly advancing field, translating complex guidelines into actionable knowledge for clinical practice. It’s an essential resource for anyone dedicated to implementing the highest standards in oncology, offering clarity and context that goes beyond the published document. Tune in for a focused exploration of how new research directly informs treatment pathways and patient management strategies.
Author: Language: en-us Episodes: 50

ASCO Guidelines
Podcast Episodes
Treatment of Multiple Myeloma: ASCO Living Guideline Update 2026.1.1 [not-audio_url] [/not-audio_url]

Duration: 17:45
Dr. Rahul Banerjee joins the podcast to discuss the latest update to the living guideline on the treatment of multiple myeloma. He explains how sensational results from the MajesTEC-3 trial, which evaluated teclistamab p…
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma Guideline [not-audio_url] [/not-audio_url]

Duration: 17:31
Drs. Tina Lockwood and Stacy Gray share the newly released evidence-based guideline on circulating tumor DNA (ctDNA) testing from ASCO. They highlight recommendations on when ctDNA testing should be offered—including sce…
Systemic Treatment of Thyroid Cancer Guideline [not-audio_url] [/not-audio_url]

Duration: 23:25
Dr. Nabil Saba shares the first evidence-based guideline on thyroid cancer from ASCO. He highlights recommendations on first- and subsequent-line systemic treatment – including multikinase inhibitors (MKIs), genomically…
Patient-Clinician Communication Guideline Update [not-audio_url] [/not-audio_url]

Duration: 31:22
Dr. Timothy Gilligan and Dr. Calvin Chou discuss the updated guideline on patient-clinician communication in oncology. They highlight clinical recommendations and strategies on topics such as communication skills and pra…
White Blood Cell Growth Factors Guideline Update [not-audio_url] [/not-audio_url]

Duration: 23:22
Dr. Bishal Gyawali and Dr. Tessa Cigler share the new, comprehensive, evidence-based update of the ASCO guideline on the use of hematopoietic colony-stimulating factors in patients with cancer. They discuss recommendatio…